Posts

CSL and Alentis strike up to US$1.6 billion drug-development deal

on

Recent pharma deals: AstraZeneca backs ivonescimab

on

Bayer plans $2.2 billion Ohio pharmaceutical manufacturing campus

on

Possible match: NTx raises $47.5M for RNA manufacturing

on

Asia pharma deal roundup: AZ backs ivonescimab, Novo licenses Hengrui’s GLP-1/GIP drug, Merck targets KRAS

on

AstraZeneca backs Summit with $2 billion stake and cancer-drug collaboration

on

Pharma deals spotlight China’s growing role in drug pipelines

on

Pharma deal headlines: AstraZeneca backs ivonescimab, Novo licenses Hengrui’s obesity candidate

on

Novartis strikes potential $7.8 billion Abogen deal for in vivo autoimmune therapy

on

Regeneron plans obesity-drug and cholesterol-therapy combination

on

Ultragenyx’s MPS IIIA Gene Therapy Application Validated by EMA

on

Talus Bio’s Ptarmigan-1 aims to find drug targets without protein structures

on

Foghorn cuts 40% of staff after ending Lilly cancer programs

on